Refractory Aggressive Non-Hodgkin's Lymphoma Clinical Trial
Official title:
Phase II Evaluation Of GROC (Gemcitabine- Rituximab-Oxaliplatin Combination) Given Every 14 Days For The Treatment Of Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma
Study Proposal:
Other drugs where synergy with Gemcitabine has been observed are Cisplatinum, Taxol,
Taxotere, Etoposide and alkylating agents. However in view of Oxaliplatin's superior
activity as a single agent against lymphoma, the combination of Gemcitabine with Oxaliplatin
is more attractive and should be explored in this group of disorders. Based on these data
and considering the advantage of its favorable toxicity profile, we propose a phase II study
in patients with either refractory or relapsing aggressive non-Hodgkin's lymphomas including
peripheral T-cell lymphomas which are known to have a poor outcome when compared with
equivalent aggressive B-cell lymphomas.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment